Karen Tornøe

2.1k total citations · 1 hit paper
28 papers, 1.5k citations indexed

About

Karen Tornøe is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Neurology. According to data from OpenAlex, Karen Tornøe has authored 28 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 11 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Neurology. Recurrent topics in Karen Tornøe's work include Diabetes Treatment and Management (9 papers), Neuroblastoma Research and Treatments (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Karen Tornøe is often cited by papers focused on Diabetes Treatment and Management (9 papers), Neuroblastoma Research and Treatments (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Karen Tornøe collaborates with scholars based in Denmark, United States and Canada. Karen Tornøe's co-authors include John B. Buse, Søren Rasmussen, Steven P. Marso, Johannes F.E. Mann, Bernard Zinman, David D. Ørsted, Neil R Poulter, Kirstine Brown‐Frandsen, Jens J. Holst and Michael A. Nauck and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Karen Tornøe

27 papers receiving 1.5k citations

Hit Papers

Liraglutide and Renal Outcomes in Type 2 Diabetes 2017 2026 2020 2023 2017 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Liraglutide and Renal Outcomes in Type 2 Diabetes
    2017 859 citations Johannes F.E. Mann, David D. Ørsted et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karen Tornøe Denmark 14 1.1k 553 482 221 192 28 1.5k
Florian M.M. Baeres Denmark 13 950 0.9× 470 0.8× 436 0.9× 219 1.0× 109 0.6× 31 1.9k
Marcin Zychma Poland 14 1.5k 1.3× 799 1.4× 566 1.2× 374 1.7× 74 0.4× 24 1.8k
Irfan Vardarli Germany 15 773 0.7× 320 0.6× 405 0.8× 96 0.4× 58 0.3× 32 1.1k
Daisuke Nagata Japan 22 438 0.4× 664 1.2× 384 0.8× 79 0.4× 317 1.7× 48 1.7k
Li Yao Japan 14 529 0.5× 470 0.8× 248 0.5× 80 0.4× 76 0.4× 23 1.4k
Søren Rasmussen Denmark 27 2.6k 2.3× 951 1.7× 1.0k 2.1× 476 2.2× 72 0.4× 87 3.2k
Jason Brett United States 13 1.7k 1.6× 824 1.5× 637 1.3× 418 1.9× 87 0.5× 17 1.9k
Stefan Aczél Austria 21 523 0.5× 369 0.7× 349 0.7× 125 0.6× 180 0.9× 38 1.4k
Joni H. Hansson United States 9 944 0.9× 1.6k 2.9× 199 0.4× 104 0.5× 51 0.3× 12 2.1k
Atsuhisa Sato Japan 18 916 0.8× 354 0.6× 255 0.5× 115 0.5× 78 0.4× 29 1.4k

Countries citing papers authored by Karen Tornøe

Since Specialization
Citations

This map shows the geographic impact of Karen Tornøe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen Tornøe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen Tornøe more than expected).

Fields of papers citing papers by Karen Tornøe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen Tornøe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen Tornøe. The network helps show where Karen Tornøe may publish in the future.

Co-authorship network of co-authors of Karen Tornøe

This figure shows the co-authorship network connecting the top 25 collaborators of Karen Tornøe. A scholar is included among the top collaborators of Karen Tornøe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karen Tornøe. Karen Tornøe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mora, Jaume, Gcf Chan, Daniel A. Morgenstern, et al.. (2025). The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. Nature Communications. 16(1). 1636–1636. 3 indexed citations
2.
Mora, Jaume, Godfrey Chi Fung Chan, Daniel A. Morgenstern, et al.. (2024). Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma.. Journal of Clinical Oncology. 42(16_suppl). 10032–10032. 2 indexed citations
3.
Kushner, Brian H., Jaume Mora, Gcf Chan, et al.. (2023). 129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score. Immuno-Oncology Technology. 20. 100601–100601. 1 indexed citations
4.
Bear, Misty D., Daniel A. Morgenstern, Karsten Nysom, et al.. (2022). 891P Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial. Annals of Oncology. 33. S956–S956. 6 indexed citations
5.
6.
Mora, Jaume, Gcf Chan, Daniel A. Morgenstern, et al.. (2022). Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HR-NB): Response data and efficacy in patient (pt) subgroups.. Journal of Clinical Oncology. 40(16_suppl). e22019–e22019. 1 indexed citations
7.
8.
Perkovic, Vlado, Stephen C. Bain, George L. Bakris, et al.. (2019). SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS. Nephrology Dialysis Transplantation. 34(Supplement_1). 4 indexed citations
9.
10.
Gilbert, Matthew P., Stephen C. Bain, Edward Franek, et al.. (2018). Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. Annals of Internal Medicine. 170(6). 423–426. 47 indexed citations
11.
Gilbert, Matthew P., Stephen C. Bain, Edward Franek, et al.. (2018). EFFECT OF LIRAGLUTIDE ON CARDIOVASCULAR OUTCOMES IN ELDERLY PATIENTS IN THE LEADER TRIAL. Journal of the American College of Cardiology. 71(11). A1718–A1718. 1 indexed citations
12.
Nauck, Michael A., Karen Tornøe, Søren Rasmussen, Marianne Bach Treppendahl, & Steven P. Marso. (2018). Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial. Diabetes and Vascular Disease Research. 15(5). 465–468. 22 indexed citations
13.
Mann, Johannes F.E., David D. Ørsted, Kirstine Brown‐Frandsen, et al.. (2017). Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine. 377(9). 839–848. 859 indexed citations breakdown →
14.
Azar, Sami T., Akram Echtay, M. A. K. Omar, et al.. (2016). Efficacy and safety of liraglutide compared to sulphonylurea during R amadan in patients with type 2 diabetes ( LIRA‐R amadan): a randomized trial. Diabetes Obesity and Metabolism. 18(10). 1025–1033. 38 indexed citations
15.
Ahmann, Andrew, Helena W. Rodbard, Julio Rosenstock, et al.. (2015). Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial. Diabetes Obesity and Metabolism. 17(11). 1056–1064. 80 indexed citations
16.
Funch, Donnie, Helge Gydesen, Karen Tornøe, Atheline Major‐Pedersen, & K. Arnold Chan. (2013). A prospective, claims‐based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obesity and Metabolism. 16(3). 273–275. 71 indexed citations
17.
Tornøe, Karen, et al.. (2006). PACAP 1-27 and 1-38 in the Porcine Pancreas: Occurrence, Localization, and Effects. Annals of the New York Academy of Sciences. 805(1). 521–535. 1 indexed citations
18.
Tornøe, Karen, Birgitte Georg, Peter T. Schmidt, et al.. (2001). PACAP 1–38 as neurotransmitter in the porcine antrum. Regulatory Peptides. 101(1-3). 109–121. 22 indexed citations
19.
20.
Loft, Steffen, P. Larsen, Allan Rasmussen, et al.. (1995). OXIDATIVE DNA DAMAGE AFTER TRANSPLANTATION OF THE LIVER AND SMALL INTESTINE IN PIGS. Transplantation. 59(1). 16–20. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian M.M. Baeres Breakdown of academic impact, for papers by Marcin Zychma Breakdown of academic impact, for papers by Irfan Vardarli Breakdown of academic impact, for papers by Daisuke Nagata Breakdown of academic impact, for papers by Li Yao Breakdown of academic impact, for papers by Søren Rasmussen Breakdown of academic impact, for papers by Jason Brett Breakdown of academic impact, for papers by Stefan Aczél Breakdown of academic impact, for papers by Joni H. Hansson Breakdown of academic impact, for papers by Atsuhisa Sato
Rankless by CCL
2026